文献速递皮肤肿瘤药疹与重症皮肤不良反应

黑色素瘤检查点抑制剂治疗中的皮肤免疫相关不良事件

Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors.
PubMed 文献 · Br J Dermatol · 2021-02-01

本文综述了接受检查点抑制剂(CPI)治疗的晚期恶性黑色素瘤成人患者中皮肤免疫相关不良事件(IrAEs)的临床表现。抗CTLA4治疗的皮肤IrAEs发生率高于抗PD1/PDL1治疗;低级别皮肤IrAEs常见且通常支持治疗并继续CPI;白癜风样脱色素是黑色素瘤良好预后指标;危及生命事件如中毒性表皮坏死松解症罕见。识别预测生物标志物仍是未满足需求,皮肤科医生参与多学科评估日益重要。

要点

  • 抗CTLA4治疗相关皮肤IrAEs发生率高于抗PD1/PDL1治疗。
  • 低级别皮肤IrAEs常见,通常支持治疗并继续CPI治疗。
  • 白癜风样脱色素是黑色素瘤患者的良好预后指标。

核心结论

  • CPI治疗黑色素瘤患者中皮肤IrAEs常见,表现多样,低级别多可支持治疗并继续CPI,白癜风样脱色素提示良好预后。

研究设计与样本

  • 本文为文献综述,检索范围包括临床试验、病例系列和病例报告,对象为接受抗CTLA4、抗PD1/PDL1或联合治疗的黑色素瘤及其他癌症成人患者。

主要发现

  • 抗CTLA4治疗的皮肤IrAEs发生率高于抗PD1/PDL1治疗。
  • 低级别皮肤IrAEs常见,通常支持治疗并继续CPI治疗。
  • 延迟出现的皮肤IrAEs可能与巧合皮肤病难以区分。
  • 白癜风样脱色素是黑色素瘤患者的良好预后指标。
  • 危及生命的不良事件包括中毒性表皮坏死松解症罕见。

关键数值与推荐

  • 抗CTLA4治疗相关皮肤IrAEs发生率高于抗PD1/PDL1治疗。
  • 低级别皮肤IrAEs通常支持治疗并继续CPI治疗。
  • 白癜风样脱色素是黑色素瘤良好预后指标。
  • 中毒性表皮坏死松解症等危及生命事件罕见。

临床怎么用

  • 皮肤科医生应参与CPI治疗黑色素瘤患者的多学科评估和管理。
  • 对低级别皮肤IrAEs可支持治疗并继续CPI治疗。
  • 需注意延迟出现的皮肤IrAEs与巧合皮肤病鉴别。

局限性

  • 识别预测危及生命IrAEs的生物标志物仍是未满足需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Checkpoint inhibitor (CPI) therapy has vastly improved long-term outcomes in metastatic malignant melanoma (MMM). Therapy takes the form of monoclonal antibody infusions that target immune cell checkpoint proteins, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and programmed death 1/programmed death ligand 1 (PD1/PDL1). Cutaneous immune-related adverse effects (IrAEs) are frequent in patients with MMM treated with CPIs. Our aim was to review the clinical presentations of cutaneous IrAEs associated with CPI therapy in adult patients with MMM. We carried out a literature review of clinical trials, case series and case reports of patients with melanoma and those with other cancers treated with anti-CTLA4, anti-PD1/PDL1, or a combination of these therapies. Diverse clinical presentations of cutaneous IrAEs are recognized. Anti-CTLA4 therapy has a higher associated rate of cutaneous IrAEs than anti-PD1/PDL1 therapies. Low-grade cutaneous IrAEs are common and are usually managed supportively while continuing CPI therapy. Delayed presentations arising after established use of CPIs can make therapy-associated cutaneous IrAEs difficult to distinguish from coincidental dermatological disease. Vitiligo-like depigmentation is a good prognostic indicator of outcome in patients with melanoma. Life-threatening adverse events including toxic epidermal necrolysis are rare. The identification of predictive biomarkers that highlight patients at risk of life-threatening IrAEs remains an unmet need. The involvement of dermatologists in the multidisciplinary assessment of cutaneous IrAEs is increasingly pertinent in the management and care of CPI-treated patients with melanoma.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Gault A, Anderson AE, Plummer R, et al. Cutaneous immune-related adverse events in patients with melanoma treated with checkpoint inhibitors. Br J Dermatol. 2021. PMID: 33393076. doi:10.1111/bjd.19750

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。